BRIEF-EMA's CHMP Approves New Manufacturing Site For Active Substance Of COVID-19 Vaccine Nuvaxovid

Reuters | Updated: 05-07-2022 15:20 IST | Created: 05-07-2022 15:15 IST

BRIEF-EMA's CHMP Approves New Manufacturing Site For Active Substance Of COVID-19 Vaccine Nuvaxovid — European Medicines Agency

European Medicines Agency:

* EMA: EMA'S CHMP APPROVED A NEW MANUFACTURING SITE FOR THE ACTIVE SUBSTANCE OF COVID-19 VACCINE NUVAXOVID: 05/07/2022 Further company coverage:

TRENDING

1

ROI-The energy transition is starting to feed itself: Maguire

ROI-The energy transition is starting to feed itself: Maguire

Global

2

Georgia block party shooting kills two, injures dozens

Georgia block party shooting kills two, injures dozens

Global

3

Brazil's Flavio Bolsonaro beats polls in presidential vote, faces Lula in runoff

Brazil's Flavio Bolsonaro beats polls in presidential vote, faces Lula in ru...

Global

4

Paraguay opposition candidate wins Asuncion mayor's race in gauge of 2028 vote

Paraguay opposition candidate wins Asuncion mayor's race in gauge of 2028 vo...

Global

PERSPECTIVES AND INSIGHTS

Beyond Megawatts: Why Clean Energy’s Real Test Is Creating Jobs, Skills and Better Livelihoods

Beyond English-Led AI: How Local Languages Could Unlock New Markets, Jobs and Public Services

From EVs to AI: Why the Future of Global Manufacturing May Depend on Small Businesses

Climate Tariffs Could Reshape Who Wins and Loses Across Global Value Chains

DevShots

Latest News

Connect us on

Facebook Twitter LinkedIn Quora Youtube

Google News RSS

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

Name

Email

Message

By submitting, you agree that we may use your email address to respond.

Web Analytics Made Easy - Statcounter